{
  "ticker": "LLY",
  "target_date": "2025-07-17",
  "actual_date": "2025-07-17",
  "collected_at": "2025-12-08T12:01:40.471932",
  "price": {
    "open": 783.91,
    "high": 787.11,
    "low": 757.24,
    "close": 758.7168579101562,
    "volume": 4107300,
    "change_1d_pct": -3.58,
    "change_7d_pct": -2.08,
    "change_30d_pct": 1.43
  },
  "technicals": {
    "rsi_14": 38.02,
    "sma_20": 778.06,
    "sma_50": 763.83,
    "macd": 0.75,
    "macd_signal": 2.345,
    "macd_histogram": -1.595,
    "bb_upper": 798.93,
    "bb_lower": 757.19,
    "price_vs_sma20_pct": -2.49,
    "price_vs_sma50_pct": -0.67,
    "volume_ratio": 1.3
  },
  "fundamentals": {
    "market_cap": 893310730240,
    "pe_ratio": 48.823647,
    "forward_pe": 43.975754,
    "price_to_book": 37.51847,
    "price_to_sales": 15.03389,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.39,
    "pct_from_52w_low": 59.75
  },
  "macro": {
    "spy": {
      "price": 626.3,
      "change_1d_pct": 0.61,
      "change_7d_pct": 0.64
    },
    "vix": {
      "level": 16.52,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.46
    },
    "dollar_index": {
      "level": 98.73
    },
    "gold": {
      "price": 3340.1
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?",
      "source": "Yahoo",
      "datetime": 1752759900,
      "summary": "LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.",
      "url": "https://finnhub.io/api/news?id=f68a23763a8cc6c1054870a6bb24f1e66abc3d1c622ead267d08ccc751476d51"
    },
    {
      "headline": "3 Stocks Including Grab Holdings That May Be Undervalued For Your Portfolio",
      "source": "Yahoo",
      "datetime": 1752752273,
      "summary": "Over the last 7 days, the United States market has remained flat, yet it has experienced a notable 12% rise over the past year with earnings forecasted to grow by 15% annually. In such an environment, identifying undervalued stocks can offer potential opportunities for investors seeking to enhance t",
      "url": "https://finnhub.io/api/news?id=7bb93a9241c8ad81712113ab1172c1cf54fc6e06abf3c04322c0ec797ad94a8c"
    },
    {
      "headline": "This Pick Withstood the GLP-1 Challenge. Stick With the Stock.",
      "source": "Yahoo",
      "datetime": 1752728400,
      "summary": "One year ago, we recommended buying  ResMed  stock after concerns that weight loss drugs would hurt demand for its sleep apnea treatments knocked shares down.  The market was concerned a new  Eli Lilly  pill would reduce patients\u2019 obstructive sleep apnea, or OSA, enough to lower demand for ResMed\u2019s ",
      "url": "https://finnhub.io/api/news?id=f34de7c293b28fbb2adaae0364a37e9a5729bac4aeb879e72bb2188e6d87b529"
    },
    {
      "headline": "Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates",
      "source": "Yahoo",
      "datetime": 1752693901,
      "summary": "Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +4.14% and +4.13%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=cf5628029b83c4f3bf6ee731b1e9b48bcf08d84faab4c7761a8c57114cc3721b"
    },
    {
      "headline": "Johnson & Johnson (JNJ) Surpasses Q2 Earnings and Revenue Estimates",
      "source": "Yahoo",
      "datetime": 1752693601,
      "summary": "Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +4.14% and +4.13%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=ab4df90a478d68601da7f57bdc641a6260c222f8c7b4e33e948841d0828c33bd"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199300.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000176/xslF345X05/wk-form4_1750199300.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199159.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000174/xslF345X05/wk-form4_1750199159.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198988.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000172/xslF345X05/wk-form4_1750198988.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198711.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000170/xslF345X05/wk-form4_1750198711.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198504.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000168/xslF345X05/wk-form4_1750198504.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}